Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineDarolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

The study included 1,306 patients (darolutamide: 651, placebo: 655), with 86.1% having metastatic disease at the time of diagnosis. At the primary analysis’s data cutoff date (October 25, 2021), the risk of death in the darolutamide group was 32.5% lower than in the placebo group. Adverse events were comparable in both groups, and the most common adverse events (occurring in 10% of patients) were most common during the overlapping docetaxel treatment period in both groups.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form